Merck’s Keytruda combo wows again, acing PhIII overall survival goal for lung cancer early

Merck’s Keytruda team can chalk up another big win in the race for PD-1/L1 dominance. Their checkpoint inhibitor added to chemo in a pivotal study delivered “significant” benefits in overall survival as well as progression-free survival among frontline non-small cell lung cancer patients — one of the big prizes in the rivalry over a mega-blockbuster … Continue reading Merck’s Keytruda combo wows again, acing PhIII overall survival goal for lung cancer early